Key Highlights
- Celularity established a domestic Manufacturing Partnership with MuseCell Innovations at its New Jersey facility.
- The partnership covers production of Dezawa MuseCells and derived exosome products.
- The long-term deal is estimated to generate more than $300 million in cumulative purchase orders.
- The arrangement is expected to create approximately 200 high-tech roles over the next five years; shares closed up 139% at $2.10.
A Domestic Manufacturing Partnership
Celularity Inc. (NASDAQ:CELU) has entered a domestic manufacturing partnership with MuseCell Innovations to begin production of Dezawa MuseCells and their derived exosome products at Celularity's New Jersey site. Dezawa MuseCells are a class of naturally occurring pluripotent-like stem cells first characterized by Dr. Mari Dezawa, while exosomes are small cell-derived particles increasingly studied as delivery vehicles and therapeutic agents in regenerative medicine.
By anchoring production domestically, the partnership positions Celularity (NASDAQ:CELU) to Supply MuseCell-derived material from an established U.S. manufacturing base rather than relying on external or overseas production capacity, a structure that can matter for supply-chain reliability in cell-therapy manufacturing.
Deal Scope and Economic Impact
The companies estimate the long-term agreement could generate more than $300 million in cumulative purchase orders over its term, a substantial figure relative to Celularity's current market size. Beyond the direct manufacturing revenue, the deal is expected to create approximately 200 high-tech jobs over the next five years at the New Jersey facility, reflecting the scale-up in production capacity the partnership is intended to support.
Why the Announcement Moved the Stock
Celularity (NASDAQ:CELU) shares closed up 139% at $2.10 following the announcement, one of the largest single-day moves among today's biopharma updates. A jump of this magnitude on a manufacturing and supply agreement — rather than clinical trial data — reflects how significant an over $300 million Revenue estimate is relative to the company's prior valuation, alongside the signal that a external partner is committing to a multi-year production relationship at Celularity's facility.
What to Watch Going Forward
As with any long-term manufacturing agreement, the pace at which purchase orders are actually placed and fulfilled will determine how quickly the estimated $300 million figure translates into realized revenue. Investors will likely look for updates on production ramp-up timelines and initial order volumes as the partnership moves from agreement to active manufacturing.
What did Celularity announce?
Celularity (NASDAQ:CELU) announced a domestic manufacturing partnership with MuseCell Innovations to produce Dezawa MuseCells and derived exosome products at its New Jersey site.
How large is the deal estimated to be?
The long-term agreement is estimated to generate over $300 million in cumulative purchase orders.
How many jobs is the partnership expected to create?
The partnership is expected to create approximately 200 high-tech roles over the next five years.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...